65,437 trials
Cognition - Other
Primary: Tonic Alertness (Mean Reaction Time) — 281; 279 Milliseconds — p=0.79
Asthma
Primary: Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) Averaged Over Treatment Period — 0.16; 0.07 Liters
Acute Myeloid Leukemia
Primary: Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant — 2; 3; 11 participants
Sensitivity in Esophagus
Primary: Time to Visual Analogue Scale 7 (VAS7) During Thermal Stimulation at 1.5 Hours Post-Dose. — 84.0; 86.9 seconds
Physical Activity · Weight
Primary: Physical Activity (Steps/Day) — 2956; 2994 steps/day
Inflammation
Primary: Serum ln(TNF-a) — 0.66; 0.74; 0.71; 0.11 pg/ml (raw TNF-a) — p=0.03
Age-Related Maculopathy · Choroidal Neovascularization
Primary: Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months — 5.9; 7.6; 16.4 Letters
Cervical Cancer
Primary: HPV Identification — 95; 142; 78 biopsies
Contraceptive Usage · Vaginal Epithelial Disruption
Primary: Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported. — 0.01; -0.005; -0.02; .007 mm
Anxious Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HAM-D) Total Score. — 14.249; 16.307 Units on a scale
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001
Corneal Neovascularization
Primary: Incidence and Severity of Ocular Adverse Event — 0 participants
Gingival Recession
Primary: Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site. — 95.3 percentage of participants — p=<0.0001
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
Labor Augmentation
Primary: Uterine Tachysystole — 50; 41 participants